Abstract
Background We previously described the KINSSHIP syndrome, an autosomal dominant disorder associated with intellectual disability (ID), mesomelic dysplasia and horseshoe kidney,caused by de novo variants in the degron of AFF3. Mouse knock-ins and overexpression in zebrafish provided evidence for a dominant-negative (DN) mode-of-action, wherein an increased level of AFF3 resulted in pathological effects.
Methods Evolutionary constraints suggest that other mode-of-inheritance could be at play. We challenged this hypothesis by screening ID cohorts for individuals with predicted-to-be deleterious variants in AFF3. We used both animal and cellular models to assess the deleteriousness of the identified variants.
Results We identified an individual with a KINSSHIP-like phenotype carrying a de novo partial duplication of AFF3 further strengthening the hypothesis that an increased level of AFF3 is pathological. We also detected seventeen individuals displaying a milder syndrome with either heterozygous LoF or biallelic missense variants in AFF3. Consistent with semi-dominance, we discovered three patients with homozygous LoF and one compound heterozygote for a LoF and a missense variant, who presented more severe phenotypes than their heterozygous parents. Matching zebrafish knockdowns exhibit neurological defects that could be rescued by expressing human AFF3 mRNA, confirming their association with the ablation of aff3. Conversely, some of the human AFF3 mRNAs carrying missense variants identified in affected individuals did not complement. Overexpression of mutated AFF3 mRNAs in zebrafish embryos produced a significant increase of abnormal larvae compared to wild-type overexpression further demonstrating deleteriousness. To further assess the effect of AFF3 variation, we profiled the transcriptome of fibroblasts from affected individuals and engineered isogenic cells harboring +/+, DN/DN, LoF/+, LoF/LoF or DN/LoF AFF3 genotypes. The expression of more than a third of the AFF3 bound loci is modified in either the DN/DN or the LoF/LoF lines. While the same pathways are affected, only about one-third of the differentially expressed genes are common to these homozygote datasets, indicating that AFF3 LoF and DN variants largely modulate transcriptomes differently, e.g. the DNA repair pathway displayed opposite modulation.
Conclusions Our results and the high pleiotropy shown by variation at this locus suggest that minute changes in AFF3 function are deleterious.
Competing Interest Statement
Annabelle Tuttle, Houda Zghal Elloumi and Chaofan Zhang are employees of GeneDx and Desiree DeMille works for ARUP Laboratories. James R. Lupski has stock ownership in 23andMe and is a paid consultant for Genome International. Claudia M.B. Carvalho provides consulting services for Ionis Pharmaceuticals. The other authors have no competing interests to declare.
Funding Statement
This work was supported by grants from the Swiss National Science Foundation (31003A_182632 and IZSTZ0_216615 to AR), the Lejeune Foundation (#1838-2019A to AR), the Blackswan Foundation (to AR), a PRIN 2020 grant from the Italian Ministry of Universities and Research (20203P8C3X to AB), and the US National Institutes of Health (NS105078 and HG011758 to JRL). This study makes use of data generated by the DECIPHER community. Funding for the DECIPHER project was provided by the Wellcome Trust [grant number WT223718/Z/21/Z]. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Informed consent forms were obtained for all affected individuals or their guardians participating in this study. The current study was approved by the CER (Commission d'éthique de la recherche) of the canton of Vaud (Protocol number: CER-VD 2021-01400). This research complies with the principles of the Declaration of Helsinki.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
Data produced in the present study are available upon reasonable request to the authors. The HEK293T and fibroblast RNA-seq reads are deposited in GEO under accession GSE241621 (token otezqcsslbctbyx) and GSE246554 (token wxibcyqatdyphkl), and will be available from August 2024.
List of abbreviations
- ID
- intellectual disabilities
- DD
- developmental delay
- DN
- dominant-negative
- LoF
- loss-of-function
- +
- wild-type allele
- NHD
- N-terminal homology domain
- CHD
- C-terminal homology domains
- ALF
- AF4-LAF4-FMR2 domain
- TAD
- transactivation domain
- NLS
- nuclear/nucleolar localization sequence
- SECs
- transcriptional super elongation complexes
- P-TEF
- positive transcription elongation factor
- MLLT
- myeloid/lymphoid or mixed-lineage leukemia; translocated to
- ELL
- Elongation Factor for RNA Polymerase II
- ELLbow
- ELL-binding domain
- pLI
- probability of being loss-of-function intolerant
- pLOEUF
- loss-of-function observed/expected upper bound fraction
- PTU
- 1-phenyl 2-thiourea
- K22-K26
- KINSSHIP patients 22 to 26
- DUP
- patient with partial duplication of AFF3
- L1-L14
- patients 1 to 14 with loss-of-function variants
- B1-B7
- patients 1 to 7 with biallelic missense variants
- ADHD
- attention deficit hyperactivity disorder
- EEG
- Electroencephalography
- ASD
- autism spectrum disorder
- KD
- knock-down
- Dpf
- days post fertilization
- IOD
- inter-ocular distance
- HW
- head width
- Un
- Untreated
- M
- mock
- Wt
- wild-type
- MAF
- minor allele frequency
- DEG
- differentially expressed genes
- MTAG-associated
- associated by multi-trait analysis of GWAS
- BMI
- body mass index
